JP2013514367A5 - - Google Patents

Download PDF

Info

Publication number
JP2013514367A5
JP2013514367A5 JP2012544740A JP2012544740A JP2013514367A5 JP 2013514367 A5 JP2013514367 A5 JP 2013514367A5 JP 2012544740 A JP2012544740 A JP 2012544740A JP 2012544740 A JP2012544740 A JP 2012544740A JP 2013514367 A5 JP2013514367 A5 JP 2013514367A5
Authority
JP
Japan
Prior art keywords
item
salt according
items
ring
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012544740A
Other languages
English (en)
Japanese (ja)
Other versions
JP5634526B2 (ja
JP2013514367A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/060439 external-priority patent/WO2011084453A1/en
Publication of JP2013514367A publication Critical patent/JP2013514367A/ja
Publication of JP2013514367A5 publication Critical patent/JP2013514367A5/ja
Application granted granted Critical
Publication of JP5634526B2 publication Critical patent/JP5634526B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012544740A 2009-12-15 2010-12-15 代謝性疾患を処置するためのｐｐａｒ温存チアゾリジンジオン塩 Active JP5634526B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28676509P 2009-12-15 2009-12-15
US61/286,765 2009-12-15
PCT/US2010/060439 WO2011084453A1 (en) 2009-12-15 2010-12-15 Ppar-sparing thiazolidinedione salts for the treatment of metabolic diseases

Publications (3)

Publication Number Publication Date
JP2013514367A JP2013514367A (ja) 2013-04-25
JP2013514367A5 true JP2013514367A5 (OSRAM) 2013-06-06
JP5634526B2 JP5634526B2 (ja) 2014-12-03

Family

ID=43501294

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012544740A Active JP5634526B2 (ja) 2009-12-15 2010-12-15 代謝性疾患を処置するためのｐｐａｒ温存チアゾリジンジオン塩

Country Status (16)

Country Link
US (2) US8912335B2 (OSRAM)
EP (1) EP2513070B1 (OSRAM)
JP (1) JP5634526B2 (OSRAM)
KR (3) KR20120107493A (OSRAM)
CN (1) CN102753539B (OSRAM)
AU (1) AU2010340055B2 (OSRAM)
CA (1) CA2783468C (OSRAM)
DK (1) DK2513070T3 (OSRAM)
ES (1) ES2658168T3 (OSRAM)
HU (1) HUE038042T2 (OSRAM)
MX (1) MX2012006725A (OSRAM)
NO (1) NO2513070T3 (OSRAM)
NZ (1) NZ600390A (OSRAM)
PL (1) PL2513070T3 (OSRAM)
RU (1) RU2564661C2 (OSRAM)
WO (1) WO2011084453A1 (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE038042T2 (hu) 2009-12-15 2018-09-28 Cirius Therapeutics Inc PPAR helyettesítõ tiazolidindion sók metabolikus betegségek kezelésére
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
JP2016506401A (ja) 2012-12-21 2016-03-03 サノフイ 二重ｇｌｐ１／ｇｉｐまたは三方ｇｌｐ１／ｇｉｐ／グルカゴンアゴニストとしてのエキセンジン−４誘導体
JP6498195B2 (ja) 2013-07-22 2019-04-10 メタボリック ソリューションズ ディベロップメント カンパニー， エルエルシー 代謝疾患を処置するためのｐｐａｒ節約化合物
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
WO2019154958A1 (en) 2018-02-08 2019-08-15 Enyo Pharma Use of modulators of neet proteins for the treatment of infection
CN111689934B (zh) * 2020-06-24 2022-08-02 郑州大学 14-脱羟-13-脱氢穿心莲内酯-12-磺酸钾的单晶体及制备方法
GB202210503D0 (en) 2022-07-18 2022-08-31 Univ Court Univ Of Glasgow Materials and methods for treatment of chronic myeloid leukemia (CML)

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
US4582839A (en) * 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
WO1985004170A1 (fr) 1984-03-21 1985-09-26 Takeda Chemical Industries, Ltd. Derives de thiazolidinedione, leur procede de preparation et compositions medicinales les contenant
CN1003445B (zh) 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
WO1986002073A1 (fr) 1984-10-03 1986-04-10 Takeda Chemical Industries, Ltd. Derives de thiazolidinedione, procede de preparation et composition pharmaceutique les contenant
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US5167228A (en) 1987-06-26 1992-12-01 Brigham And Women's Hospital Assessment and modification of endogenous circadian phase and amplitude
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5143930A (en) 1990-02-07 1992-09-01 Sankyo Company, Limited Thiazolidine derivatives with anti-diabetic activity, their preparation and their use
US5356913A (en) 1990-02-09 1994-10-18 The Upjohn Company Use of insulin sensitizing agents to treat hypertension
WO1992018501A1 (en) * 1991-04-11 1992-10-29 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
US5441971A (en) 1991-04-11 1995-08-15 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
NO302471B1 (no) 1991-12-26 1998-03-09 Sankyo Co Tiazolidinforbindelser og farmasöytisk preparat
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5798375A (en) 1995-07-03 1998-08-25 Sankyo Company, Limited Treatment of arteriosclerosis and xanthoma
US7407978B2 (en) 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
WO2000066102A2 (en) 1999-04-29 2000-11-09 City Of Hope Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (age's)
US6331596B1 (en) 1999-06-28 2001-12-18 Basf Corporation Method of preparing carbamate-functional polymers
DK1192137T3 (da) 1999-06-30 2013-11-11 Amgen Inc Forbindelser til modulering af PPAR-gamma aktivitet
WO2001082916A2 (en) 2000-05-03 2001-11-08 Tularik Inc. Combination therapeutic compositions and methods of use
JP2004514703A (ja) 2000-12-01 2004-05-20 ノバルティス　アクチエンゲゼルシャフト 有機化合物の組合せ剤
AU2002311057A1 (en) 2001-04-26 2002-11-11 Leciva, A.S. Method for obtaining pioglitazone as an antidiabetic agent
AU2002337749A1 (en) 2001-09-28 2003-04-07 Teva Pharmaceutical Industries Ltd. Pioglitazone hydrochloride
AUPS236902A0 (en) 2002-05-16 2002-06-13 Northern Sydney Area Health Service Composition and method for treating hypertension
AU2003272072A1 (en) 2002-07-16 2004-02-02 Cadila Healthcare Limited A process to prepare pioglitazone via several intermediates.
US20060083784A1 (en) 2002-08-07 2006-04-20 Smithkline Beecham Corporation Amorphous pharmaceutical compositions
US7230016B2 (en) 2003-05-13 2007-06-12 Synthon Ip Inc. Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same
US20070078170A1 (en) 2003-08-28 2007-04-05 Khanduri Chandra H Process for the preparation of pioglitazone
AR047541A1 (es) 2004-02-13 2006-01-25 Sandoz Ag Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
JP4475983B2 (ja) 2004-03-03 2010-06-09 学校法人日本大学 Ｂｍａｌ１を阻害する方法
AU2005288080B2 (en) 2004-09-28 2011-10-13 Otsuka Pharmaceutical Co., Ltd. Carbostyril compound
MX2008011870A (es) 2006-03-16 2009-02-10 Metabolic Solutions Dev Compan Terapias de combinacion de analogos de tiazolidindiona y agonistas glucocorticoides.
CA2646207C (en) 2006-03-16 2016-01-19 Metabolic Solutions Development Company Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease
ES2388555T3 (es) 2006-03-16 2012-10-16 Metabolic Solutions Development Company Llc Análogos de tiazolidindiona
NZ597381A (en) 2007-09-14 2013-03-28 Metabolic Solutions Dev Co Llc Thiazolidinedione analogues for the treatment of diabetes and inflammatory diseases
US8304441B2 (en) 2007-09-14 2012-11-06 Metabolic Solutions Development Company, Llc Thiazolidinedione analogues for the treatment of metabolic diseases
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
DK2222272T3 (da) * 2008-08-07 2013-02-11 Pulmagen Therapeutics Inflammation Ltd Behandling af luftvejssygdom
WO2010105048A1 (en) 2009-03-12 2010-09-16 Metabolic Solutions Development Company Thiazolidinedione analogues
WO2011017244A1 (en) 2009-08-05 2011-02-10 Metabolic Solutions Development Company Polymorphs of 5-(4-(2-(5-ethylpyridin-2-yl)-2-oxoethoxy)benzyl)-1,3-thiazolidine-2,4-dione (mitoglitazone)
MX2012006734A (es) 2009-12-15 2012-07-03 Metabolic Solutions Dev Co Llc Tiazolidinadionas moderadoras de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de obesidad y otras enfermedades metabolicas.
CA2783556C (en) 2009-12-15 2017-12-12 Metabolic Solutions Development Company, Llc Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases
KR20120092712A (ko) 2009-12-15 2012-08-21 메타볼릭 솔루션스 디벨롭먼트 컴퍼니, 엘엘씨 진성 당뇨병 및 다른 대사성 질환의 치료를 위한 ｐｐａｒ 절약형 티아졸리딘디온 및 복합제
HUE038042T2 (hu) 2009-12-15 2018-09-28 Cirius Therapeutics Inc PPAR helyettesítõ tiazolidindion sók metabolikus betegségek kezelésére
AU2011242844A1 (en) 2010-04-21 2012-11-01 Metabolic Solutions Development Company, Llc Thiazolidinedione analogues

Similar Documents

Publication Publication Date Title
JP2012041349A5 (OSRAM)
JP2013537203A5 (OSRAM)
JP2016505614A5 (OSRAM)
RU2012129930A (ru) Соли тиазолидиндиона со сниженным сродством к ppar для лечения нарушений обмена веществ
JP2011513305A5 (OSRAM)
JP2016503793A5 (OSRAM)
IN2014CN00794A (OSRAM)
JP2014525420A5 (OSRAM)
JP2011522789A5 (OSRAM)
JP2016006118A5 (OSRAM)
JP2016040288A5 (OSRAM)
JP2013544276A5 (OSRAM)
JP2013531031A5 (OSRAM)
MX2010002904A (es) N-fenil-dioxo-hidropirimidinas utiles como inhibidores de virus de hepatitis c (hcv).
JP2013540713A5 (OSRAM)
JP2014508811A5 (OSRAM)
RU2007139634A (ru) Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения
JP2011500550A5 (OSRAM)
JP2006522035A5 (OSRAM)
CO6251243A2 (es) Nuevos inhibidores macrocíclicos de la replicación del virus de hepatitis c
JP2011504903A5 (OSRAM)
JP2012140436A5 (ja) 物質
JP2011516610A5 (OSRAM)
JP2007092033A5 (OSRAM)
JP2013544854A5 (OSRAM)